Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML

Leukemia

Volumn 26, Issue 2, 2012, Pages 362-365

  Van Der Jagt, A ^a   Muirhead, J ^a   Seymour, J F ^b   Bradstock, K F ^c   Paul, E ^a   Wei, A ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; DRUG MEGADOSE; HUMAN; LETTER; LEUKOCYTE COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84856751417     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.201     Document Type: Letter

References (12)

1. Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten H, Graux C et al. Cytarabine dose for acute myeloid leukemia. N Eng J Med 2011; 364: 1027-1036.
2. Fernandez H, Sun Z, Yao X, Litzow M, Luger S, Paietta E et al. Anthracycline dose intensification in acute myeloid leukemia. N Eng J Med 2009; 361: 1249.
3. Bradstock K, Matthews J, Lowenthal R, Baxter H, Catalano J, Brighton T et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481-488. (Pubitemid 40070725)
4. Bishop J, Matthews J, Young G, Szer J, Gillett A, Joshua D et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710.
5. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti M-C, Meloni G et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27: 5397-5403.
6. Buchner T, Berdel W, Schoch C, Haferlach T, Serve H, Kienast J et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480.
7. Weick J, Kopecky K, Appelbaum F, Head D, Kingsbury L, Balcerzak S et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841.
8. Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig W et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009; 113: 3903.
9. Wheatley K, Goldstone AH, Littlewood T, Hunter A, Burnett AK. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 2009; 146: 54-63.
10. Ventura G, Hester J, Smith T, Keating M. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 1988; 27: 34-37. (Pubitemid 18052629)
11. Thiebaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000; 79: 501-506.
12. Smith G, Damon L, Rugo H, Ries C, Linker C. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 15: 833-839. (Pubitemid 27075136)